Boston Scientific Corporation (BSX) Given Average Recommendation of “Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have been given a consensus rating of “Buy” by the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.91.

Several research firms recently weighed in on BSX. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the company a “buy” rating in a research note on Tuesday, October 31st. Zacks Investment Research cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. BMO Capital Markets reiterated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, December 12th. Evercore ISI began coverage on shares of Boston Scientific in a research note on Wednesday, January 3rd. They issued an “in-line” rating and a $27.00 target price for the company. Finally, Jefferies Group reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd.

Shares of Boston Scientific (NYSE:BSX) traded down $0.26 during trading hours on Tuesday, hitting $25.92. The stock had a trading volume of 1,322,627 shares, compared to its average volume of 9,707,938. The firm has a market capitalization of $35,593.24, a P/E ratio of 370.71, a P/E/G ratio of 1.88 and a beta of 0.81. Boston Scientific has a 12 month low of $23.29 and a 12 month high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. The company had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The firm’s revenue was up 9.9% compared to the same quarter last year. During the same period last year, the business posted $0.30 earnings per share. research analysts predict that Boston Scientific will post 1.37 EPS for the current fiscal year.

In other Boston Scientific news, SVP David A. Pierce sold 8,763 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $27.74, for a total transaction of $243,085.62. Following the completion of the transaction, the senior vice president now owns 24,201 shares in the company, valued at $671,335.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the business’s stock in a transaction on Tuesday, November 28th. The shares were acquired at an average price of $0.45 per share, with a total value of $183,602.70. In the last 90 days, insiders have sold 177,032 shares of company stock valued at $4,648,733. Corporate insiders own 0.74% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC bought a new position in Boston Scientific during the third quarter worth about $138,000. Steward Partners Investment Advisory LLC bought a new position in Boston Scientific during the third quarter worth about $139,000. Cerebellum GP LLC bought a new position in Boston Scientific during the fourth quarter worth about $126,000. Ironwood Investment Counsel LLC bought a new position in Boston Scientific during the third quarter worth about $204,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Boston Scientific during the third quarter worth approximately $204,000. Hedge funds and other institutional investors own 89.84% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.com-unik.info/2018/02/13/boston-scientific-corporation-bsx-given-average-recommendation-of-buy-by-brokerages.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit